Related Experiment Video
Updated: May 9, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
Market Size and Innovation: Effects of Medicare Part D on Pharmaceutical Research and Development
Margaret E Blume-Kohout1, Neeraj Sood
1Robert Wood Johnson Foundation Center for Health Policy and Department of Economics, MSC05 3060, University of New Mexico, Albuquerque, NM 87131-0001; Tel. 505-277-5304.
Abstract:
Recent evidence suggests that Medicare Part D increased prescription drug use among seniors, and increased pharmaceutical firms' revenues from sales. Previous studies also indicate that increases in market size induce pharmaceutical innovation. This paper assesses the impact of the Medicare Part D legislation on pharmaceutical research and development (R&D), using time-series data on the number of drugs entering preclinical and clinical development by therapeutic class and phase. We find that the passage and implementation of Medicare Part D is associated with significant increases in pharmaceutical R&D for therapeutic classes with higher Medicare market share.
Related Concept Videos
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Drug Dosing: Geriatric Patients
Drug Products: Biologics, Biosimilars and Interchangeables
Dose Size and Dosing Frequency: Determination Methods

